Beam Therapeutics, Inc. (BEAM)
NASDAQ:BEAM
Want to see BEAM full AI Analyst Report?
BEAM Stock Chart & Stats
$31.39
-$0.69(-2.55%)
At close: 4:00 PM EST
$31.39
-$0.69(-2.55%)
Day’s Range― - ―
52-Week Range$15.60 - $36.44
Previous CloseN/A
Volume491.48K
Average Volume (3M)1.98M
Market Cap
$2.99B
Enterprise Value$3.35B
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$250.82M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 11, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding102,879,210
10 Day Avg. Volume1,947,133
30 Day Avg. Volume1,978,969
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue20.43
Enterprise Value/Gross Profit-63.00
Enterprise Value/Ebitda-104.60
Forecast
1Y Price Target
$51.58Price Target Upside64.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.42
Revenue Forecast (FY)$70.79M
Bulls Say, Bears Say
Bulls Say
Platform & PipelineBeam’s base‑editing platform and dual in vivo/ex vivo program slate provide a durable competitive advantage: a singular core technology can generate multiple therapeutic candidates and partnership opportunities, sustaining R&D productivity and long‑term value creation.
Revenue Growth TrendConsistent TTM revenue growth indicates improving commercialization and partnership execution. That trend reduces reliance on dilutive financings over time, supports ongoing development spend, and signals gradual validation of programs or deal activity across multiple quarters.
Balance Sheet StrengthModest debt and a sizable equity base give Beam financial flexibility during multi‑year clinical development. A stronger balance sheet lowers refinancing risk, supports strategic partnerships or selective M&A, and provides runway to advance programs without immediate liquidity pressure.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow creates ongoing dependence on external capital or partner funding. Over months this increases dilution risk and can constrain program prioritization, raising execution risk if clinical or regulatory timelines slip.
Sustained Losses & Negative MarginsDeep negative margins and negative ROE reflect that operations are not yet self‑funding. If losses persist, accumulated deficits can erode shareholder equity and limit reinvestment capacity, making long‑term profitability a higher hurdle and heightening reliance on external funding.
Milestone-driven Revenue RelianceRevenue tied to partner milestones and collaborations is inherently lumpy and timing‑uncertain. That structural dependence reduces predictability of cash flows, complicates multi‑period planning, and can delay material revenue recognition if partner programs or regulatory events slip.
Beam Therapeutics News
BEAM FAQ
What was Beam Therapeutics, Inc.’s price range in the past 12 months?
Beam Therapeutics, Inc. lowest stock price was $15.60 and its highest was $36.44 in the past 12 months.
What is Beam Therapeutics, Inc.’s market cap?
Beam Therapeutics, Inc.’s market cap is $2.99B.
When is Beam Therapeutics, Inc.’s upcoming earnings report date?
Beam Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 57 days.
How were Beam Therapeutics, Inc.’s earnings last quarter?
Beam Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$1.028 by $0.118.
Is Beam Therapeutics, Inc. overvalued?
According to Wall Street analysts Beam Therapeutics, Inc.’s price is currently Undervalued.
Does Beam Therapeutics, Inc. pay dividends?
Beam Therapeutics, Inc. pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics, Inc. dividends here
What is Beam Therapeutics, Inc.’s EPS estimate?
Beam Therapeutics, Inc.’s EPS estimate is -1.11.
How many shares outstanding does Beam Therapeutics, Inc. have?
Beam Therapeutics, Inc. has 102,879,210 shares outstanding.
What happened to Beam Therapeutics, Inc.’s price movement after its last earnings report?
Beam Therapeutics, Inc. reported an EPS of -$0.91 in its last earnings report, beating expectations of -$1.028. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Beam Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BEAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beam Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.58 (64.33% Upside)
$51.58 (64.33% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.45%
12-Months-Change
Fundamentals
Return on Equity
-5.89%
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Beam Therapeutics, Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.View all BEAM earnings summariesBEAM Stock 12 Month Forecast
Average Price Target
$51.58
▲(64.33% Upside)
Technical Analysis
Denali Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Immunocore Holdings
―
Ownership Overview
3.63% Insiders
21.57% Mutual Funds
46.72% Other Institutional Investors
0.09% Public Companies and Individual Investors